Jason Harris

Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com

Articles

Vogelzang, 2018 Giants of Cancer Care® Winner, Dies at 72

September 23rd 2022

Nicholas J. Vogelzang, MD, a world-renowned genitourinary oncologist and investigator and the 2018 Giants of Cancer Care® award winner in GU cancer, died on September 20, 2022. He was 72.

Belzutifan/Cabozantinib Combo Maintains Antitumor Activity in Advanced RCC at 2 Years

September 12th 2022

Belzutifan plus cabozantanib sustained antitumor activity in patients with advanced clear cell renal cell carcinoma who previously received immunotherapy.

High-Dose MEDI5752 Induces Clinical Benefit in NSCLC at the Cost of Significant Toxicity

September 11th 2022

MEDI5752 plus chemotherapy doubled the duration of response and extended survival compared with pembrolizumab in patients with treatment-naïve nonsquamous non–small cell lung cancer.

Sacituzumab Govitecan-hziy Demonstrates Promising Efficacy in HER2-low/HER2-0 Metastatic Breast Cancer

September 10th 2022

Sacituzumab govitecan improved progression-free survival and overall response rate among patients with HER2-low or HER2 immunohistochemistry zero, hormone receptor–positive metastatic breast cancer.

Higher-Dose Rhenium-186 Nanoliposome Demonstrates OS Advantage in Recurrent Glioma

September 9th 2022

Rhenium-186 nanoliposome administered at doses exceeding 100 Gy demonstrated promising safety and efficacy results in patients with recurrent glioma.

Azacitidine/Venetoclax Combo Delivers Promising Early Results in High-Risk CML, MDS

September 8th 2022

Azacitidine plus venetoclax showed encouraging activity in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

ASTRO Releases Clinical Guidelines for Radiation Therapy in IDH-Mutant Glioma

September 1st 2022

For the first time, the American Society for Radiation Oncology has issued recommendations on the use of radiation therapy to treat patients with IDH-mutant grade 2 and grade 3 diffuse glioma, including oligodendroglioma and astrocytoma.

CTCL Is Rare, Incurable, and Potentially Lethal in Advanced Stages

August 31st 2022

Although cutaneous T-cell lymphoma, a group of non-Hodgkin T-cell lymphomas, remains a rare disease, incidence has increased steadily since the 1970s.

Biallelic Deletion of TNFRSF17 Associated With Resistance to BCMA-Targeting Therapies In Myeloma

August 28th 2022

Identifying BCMA expression, copy number variation, and point mutations can have important therapeutic implications for patients receiving BCMA-targeting CAR T-cell therapy or T-cell engagers for multiple myeloma.

Luspatercept-ammt Demonstrates Long-Term Efficacy in LR-MDS

August 24th 2022

Luspatercept, a first-in-class erythroidmaturation agent, induced high clinical activity in patients with transfusion-dependent, lower-risk myelodysplastic syndromes and ring sideroblasts who were relapsed/refractory to erythropoietin, according to findings from the phase 2 PACE-MDS study.

Analysis Reveals Racial Disparities in Timeliness of Treatment With IMRT Among Individuals With Cancer

August 22nd 2022

Non-Hispanic Black, Hispanic, and Asian patients with cancer are significantly more likely to experience delays in receiving intensity-modulated radiotherapy.

NCCN Elevates Sacituzumab Govitecan-Hziy to Preferred Recommendations in Metastatic Breast Cancer

August 10th 2022

Sacituzumab govitecan-hziy is now a category 1 preferred recommendation in triple-negative breast cancer and a category 2A preferred recommendation in HR-positive/HER2-negative disease.

Boosting Lung Cancer Screening Will Improve Survival

August 9th 2022

There is an obvious way to double survival in patients with lung cancer in the next 5 years: remove barriers to screening, especially for high-risk populations.

Temozolomide Plus Nivolumab Shows Efficacy in Previously Treated ES-SCLC

August 8th 2022

Temozolomide in combination with nivolumab induced a promising overall response rates in patients who previously received chemotherapy for extensive-stage small cell lung cancer.

Sitravatinib/Tislelizumab Combo Induces Antitumor Activity in PD-L1+ Advanced NSCLC

August 7th 2022

Sitravatinib in combination with tislelizumab demonstrated a confirmed investigator-assessed overall response rate of 30.4% in patients with PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.

Ociperlimab Plus Tislelizumab Demonstrates Antitumor Activity in PD-L1+ NSCLC

August 6th 2022

Ociperlimab, an anti-TIGIT monoclonal antibody, plus the anti–PD-L1 monoclonal antibody tislelizumab induced promising efficacy in adults with treatment-naïve, metastatic, PD-L1–positive non–small cell lung cancer, according to data from the dose-expansion cohort of the AdvanTIG-105 trial.

Avelumab/Talazoparib Combo Worthy of Further Exploration in Recurrent MMRP Endometrial Cancer

August 4th 2022

Avelumab plus talazoparib showcased a favorable toxicity profile and overall modest activity in patients with mismatch repair–proficient endometrial cancer; however, immunogenomic profiling revealed a certain subset who might derive benefit from the doublet, warranting further investigation.

Sintilimab Combo Extends PFS in Previously Treated EGFR-Mutated NSCLC

August 3rd 2022

Sintilimab in combination with a bevacizumab biosimilar plus pemetrexed and cisplatin induced a progression-free survival benefit of 2.6 months compared with chemotherapy alone for patients with EGFR-mutated, locally advanced or metastatic non–small cell lung cancer, according to interim findings from the ongoing phase 3 ORIENT-31 trial.

Low-Dose Belantamab Mafodotin/Nirogacestat Demonstrates Encouraging Clinical Activity in R/R Myeloma

July 27th 2022

Nirogacestat plus belantamab mafodotin induced promising responses with manageable safety for patients with relapsed/refractory multiple myeloma.

Neoadjuvant mFOLFIRINOX Produces Favorable OS Results Without Radiation in Borderline Resectable Pancreatic Cancer

July 27th 2022

Neoadjuvant mFOLFIRINOX induced favorable overall survival results for patients with borderline resectable pancreatic ductal adenocarcinoma when administered prior to pancreatectomy, though neoadjuvant mFOLFIRINOX followed by hypofractionated radiation therapy did not prove to be similarly effective.